As killer virus outbreaks hit unprecedented levels, nonprofit hands $37.5M to Themis to tackle Lassa/MERS vaccines
A nonprofit formed in the aftermath of the recent Ebola outbreak is handing an Austrian biotech $37.5 million to put two killer diseases on its vaccine to-do list: Lassa fever and MERS.
It’s the first deal signed since the 2017 launch of the nonprofit, which calls itself CEPI (pronounced “seppy”) – short for the Coalition for Epidemic Preparedness Innovations. The group’s goal is to build a global vaccine development fund, devoted to readying pandemic defenses during peacetime. It was formed by the governments of Norway, Germany, India, and Japan, along with the Bill and Melinda Gates Foundation, Wellcome, and the World Economic Forum.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.